June 15, 2020 / 12:18 PM / 25 days ago

BRIEF-Navidea Announces Full Enrollment In Ongoing Phase 2B Trial Of Tc99m Tilmanocept

June 15 (Reuters) - Navidea Biopharmaceuticals Inc:

* NAVIDEA BIOPHARMACEUTICALS ANNOUNCES FULL ENROLLMENT IN ITS ONGOING PHASE 2B TRIAL OF TC99M TILMANOCEPT IN RHEUMATOID ARTHRITIS (RA)

* NAVIDEA BIOPHARMACEUTICALS - STUDY IS ON TRACK FOR LAST PATIENT TO BE SCREENED, AND EVALUATED BY END OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below